New virus in india

As of June 14, India has recorded 120 new COVID-19 infections, while the active cases have decreased to 2,148 from 2,248, according to the Union Health Ministry data updated on June 14 . The death toll stood at 5,31,892, the data updated at 8 a.m. stated. Also read: The COVID-19 tally was recorded at 4.49 crores. The National Recovery Rate has been recorded at 98.81% , according to the Health Ministry website. The number of people who have recuperated from the disease surged to 4,44,59,040 and the Case Fatality Rate was recorded at 1.18% .

Scientists are scrambling to understand what role B.1.617, the variant discovered in India, will play in future surges of Covid-19. The trajectory of the variant, whether it continues spreading at its current pace or slows, will be clearer in the coming weeks. The B.1.617 variant is one of the factors driving the current crisis in India and neighboring The variant is believed more contagious than the original SARS-CoV-2 virus, but as yet there’s no clear evidence it causes more severe disease or more deaths. The same public health measures — masks and social distancing — can prevent the spread of the virus variant, experts say. And while it might have some impact on the vaccines, its mutations will likely not be enough to weaken protection against serious illness, research suggests. Yet, the B.1.617, which was initially identified in October, is being closely watched as it spreads around the world. It's now been found in at least 44 countries, including the United States, where about 3 percent of the sequenced samples are a version of the B.1.617, according to recent data from the Because of two concerning mutations, the variant from India has been given a scary nickname “double mutant,” an incorrect term that is “completely unhelpful,” said Deepta Bhattacharya, an associate professor of immunobiology at the University of Arizona College of Medicine. In fact, all the identified variants of concern — including the B.1.1.7 from the U.K., the B.1.351 from South Africa and the...

Jharkhand reported for the first time two new cases of H3N2 influenza, besides five fresh cases of COVID-19, a health department official said on Sunday. A 68-year-old woman, who was admitted to Tata Main Hospital (TMH), Jamshedpur with symptoms of cold and fever on Thursday, tested positive for influenza virus H3N2 on Saturday, the official said. After Corona, now the risk of a new sub-variant H3N2 is increasing as the virus is fastly spreading across the country, and its cases are also coming to the fore. However not a single case of the virus has been reported from the Lok Nayak Jai Prakash Narayan (LNJP) hospital so far, but in the meantime the risk of corona has also started increasing.Dr Suresh Kumar, Medical Director of Delhi's LNJP Hospital, told ANI

The WHO XBB. 1.16 a “variant under monitoring” on March 22. This means the variant has “genetic changes” that could affect its characteristics as a virus, including a possible “growth advantage” over other variants, but the epidemiological impact is not clear. The WHO is monitoring seven variants, including the BA.2 version of omicron seen in many parts of the United States. A “variant under monitoring” is considered to be of lesser concern than a “variant of interest,” which is predicted or known to be more transmissible or virulent, or able to evade antibodies, according to the WHO. The XBB. 1.5 strain, currently the most prevalent subvariant globally, is described as a variant of interest. He explains that immunity in the body’s T cells represents “one of the biggest protections,” and yet “we’re not seeing much evolution in the parts of the virus that T cells actually attack,” meaning that the impact of the mutations may be limited. “There’s no evidence that this is any more severe — and probably it’s somewhat less severe than previous strains — but it’s too early to be certain. And that’s almost certainly because of immunity.” He added that previous studies showed that many people are benefiting from the hybrid immunity that comes from a combination of previous infections and vaccination, which should offer them better protection against severe disease “for quite a bit longer, probably for a few years” — meaning that, even if they become infected with Arcturus or anoth...